BriaCell to Investigate Alleged Illegal Trading of Public Securities – Investing News Network

Random topic

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, announced today that it has approved measures to address alleged illegal trading activity of its publicly traded securities. The Company believes that certain individuals andor companies may have engaged in manipulative andor suspected illegal trading practices that may have artificially depressed its share price. As a result, BriaCell is implementing a plan to address this issue which may include legal action.
BriaCell is working to build one of the leading immuno-oncology companies in the biotech sector with a singular focus on commercializing our novel immunotherapy approach for cancer patients. While our clinical team remains dedicated to developing these desperately needed therapies, the Company recognizes that recent milestones have been achieved with the support of loyal investors who are instrumental in the ongoing development of our assets. By taking action to protect the interests of our shareholders, we are also protecting the interests of the Company and the tens of thousands of cancer patients in need of effective treatment options. To this end, BriaCell is pursuing avenues to address alleged illegal activities carried out by various parties potentially working collusively with the intent of depressing the Company's share price while undermining the interest of our shareholders.

About BriaCell Therapeutics Corp.
BriaCell is an immuno-oncology-focused biotechnology company developing targeted and effective approaches for the management of cancer. More information is available at https://briacell.com/ .
Safe Harbor
This press release contains "forward-looking statements" that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will," "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Examples of forward-looking statements in this news release include statements that the Company makes regarding the Company's plans to address alleged illegal activities carried out by various parties potentially working collusively with the intent of depressing the Company's share price which may include legal action. Forward-looking statements are based on BriaCell's current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully under the heading "Risks and Uncertainties" in the Company's most recent Management's Discussion and Analysis, under the heading "Risk Factors" in the Company's most recent Annual Information Form, and under "Risks and Uncertainties" in the Company's other filings with the Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission, all of which are available under the Company's profiles on SEDAR at www.sedar.com and on EDGAR at www.sec.gov . Forward-looking statements contained in this announcement are made as of this date, and BriaCell Therapeutics Corp. undertakes no duty to update such information except as required under applicable law.
Neither the Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contact Information
Company Contact:
William V. Williams, MD
President & CEO
1-888-485-6340
info@briacell.com
Media Relations:
Jules Abraham
Director of Public Relations
CORE IR
917-885-7378
julesa@coreir.com
Investor Relations Contact:
CORE IR
investors@briacell.com
Primary Logo
News Provided by GlobeNewswire via QuoteMedia

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, today issues a letter to shareholders from Dr. William V. Williams, BriaCell's President and CEO.
Dear BriaCell Shareholders,
I am writing this letter to share our tremendous excitement with our recent Bria-IMT™ FDA milestone, and to provide insights into our upcoming Bria-OTS™ personalized treatment program. We strongly believe our novel immunotherapy candidates will transform the way we treat cancer patients.
Our Lead Program and Value Driver: Bria-IMT™
Last week , we received positive feedback from the FDA and are progressing towards our pivotal study initiation for Bria-IMT™ in combination with an immune checkpoint inhibitor in advanced metastatic breast cancer (under Fast Track designation). Rather than working through multi-year Phase II and Phase III trials, successful completion of the pivotal study would allow us to subsequently submit a Biologics License Application and greatly accelerate the path to commercialization.

The FDA agreed on the eligible patient population for the study: breast cancer patients who have failed the available approved therapies. These are women in desperate need of therapy to extend their lives. The FDA also agreed on our preferred primary endpoint of survival improvement in comparison to the patient physician's choice of treatment. Note that the average survival in this very sick patient population is under one year and as little as weeks in women who have progressed through multiple regimes. These women need help!
We are speeding up clinical preparations in parallel as we finalize the pivotal study protocol with the FDA in the coming months. We have boosted our Bria-IMT™ production batches and testing capabilities required for larger scale patient dosing. Frequent and responsive FDA communication under our Fast Track status has greatly accelerated protocol review and feedback timelines. We could initiate patient dosing as early as the second quarter of 2023.
Our recently reported cash position is US$37 million. Subject to finalizing the pivotal study protocol and associated costs, we are in the enviable position of being able to drive this program forward without the need to raise additional financing.
Learning from our Top Responders: Our Bria-OTS™ Program
With BriaCell's newly issued patent , protecting the composition of matter and method of use of BriaCell's personalized off-the-shelf whole-cell immunotherapies, BriaCell expects to begin dosing advanced metastatic breast cancer patients in its Bria-OTS™ Phase I/IIa clinical study in the first half of 2023.
We believe this unique approach will maximize patient responses by "HLA matching" each patient, identifying her human leukocyte antigen (HLA) type prior to dosing through a simple saliva test. We then treat her with pre-manufactured cells that correspond to her HLA type. We call this matching approach Bria-OTS™ or Off-The-Shelf. This novel treatment approach came about when we found that the HLA type of our previously disclosed top responders matched with the Bria-IMT™ cell-line HLA type.
The treatment will be "personalized" because the cell therapy will match the HLA type of the patient, even though it is pre-manufactured.
Thank You!
As a physician who has been involved in drug development for over 25 years, I can state without hesitation that I am absolutely thrilled with our recent progress and very proud of the world-class team we have assembled at BriaCell. We continue to strive towards solutions for cancer patients whose medical needs are unmet and look forward to sharing more exciting news with you in the coming months.
I want to end this letter by thanking all our shareholders who have continued to support us throughout our journey, as well as our employees, board members, scientific advisory board, collaborators, and clinical teams who have worked tirelessly to make these clinical advancements possible. Finally, I would like to offer our sincerest thanks to our patients and their families for their patience and trust in our science and technology. I am looking forward to a great year in 2023.
Yours very truly,
William V. Williams, MD
President & CEO
BriaCell Therapeutics Corp.

About BriaCell Therapeutics Corp.
BriaCell is an immuno-oncology-focused biotechnology company developing targeted and effective approaches for the management of cancer. More information is available at https://briacell.com/ .
Safe Harbor
This press release contains "forward-looking statements" that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will," "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Examples of forward-looking statements in this news release include statements that the Company makes regarding the ability of the pivotal study to greatly accelerate the path to commercialization; the potential for the Company to make a Biologics License application for the approval of the combination regimen; the potential initiation of patient dosing in the first half of 2023; the ability to drive the pivotal study program forward without the need to raise additional funding; and the Company's ability to address alleged illegal activities intended to depress the Company's share price. Forward-looking statements are based on BriaCell's current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully under the heading "Risks and Uncertainties" in the Company's most recent Management's Discussion and Analysis, under the heading "Risk Factors" in the Company's most recent Annual Information Form, and under "Risks and Uncertainties" in the Company's other filings with the Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission, all of which are available under the Company's profiles on SEDAR at www.sedar.com and on EDGAR at www.sec.gov . Forward-looking statements contained in this announcement are made as of this date, and BriaCell Therapeutics Corp. undertakes no duty to update such information except as required under applicable law.
Neither the Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contact Information
Company Contact:
William V. Williams, MD
President & CEO
1-888-485-6340
info@briacell.com
Media Relations:
Jules Abraham
Director of Public Relations
CORE IR
917-885-7378
julesa@coreir.com
Investor Relations Contact:
CORE IR
investors@briacell.com
Primary Logo
News Provided by GlobeNewswire via QuoteMedia

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, is pleased to announce that it has received agreement and positive feedback from its End of Phase II meeting with the FDA regarding BriaCell's lead clinical candidate, Bria-IMT™ in combination with a checkpoint inhibitor (under Fast Track designation), in advanced metastatic breast cancer.
BriaCell and the FDA have agreed on the primary end point, the essential elements of the study design, and the type of patients to be enrolled in BriaCell's upcoming pivotal clinical study. This pivotal registration study will be enrolling advanced metastatic breast cancer patients for whom no approved treatment options exist.

Registration study success could lead to a Biologics License Application (BLA) submission for the approval of the combination regimen for commercialization in advanced metastatic breast cancer.
"The importance of this milestone speaks for itself and is yet another major step towards our goal to become one of the leading immuno-oncology companies," stated Dr. William V. Williams, BriaCell's President and CEO. "Jumping directly into a pivotal study shortly after receiving Fast Track status has greatly advanced our lead clinical program timetable with the ultimate goal of commercializing our novel immunotherapy approach for women with no approved treatment options."
About BriaCell Therapeutics Corp.
BriaCell is an immuno-oncology-focused biotechnology company developing targeted and effective approaches for the management of cancer. More information is available at https://briacell.com/ .
Safe Harbor
This press release contains "forward-looking statements" that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will," "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Examples of forward-looking statements in this news release include statements that the Company makes regarding to the Company upcoming pivotal clinical study and the potential for the Company to make a Biologics License Application for the approval of the combination regimen. Forward-looking statements are based on BriaCell's current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully under the heading "Risks and Uncertainties" in the Company's most recent Management's Discussion and Analysis, under the heading "Risk Factors" in the Company's most recent Annual Information Form, and under "Risks and Uncertainties" in the Company's other filings with the Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission, all of which are available under the Company's profiles on SEDAR at www.sedar.com and on EDGAR at www.sec.gov . Forward-looking statements contained in this announcement are made as of this date, and BriaCell Therapeutics Corp. undertakes no duty to update such information except as required under applicable law.
Neither the Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contact Information
Company Contact:
William V. Williams, MD
President & CEO
1-888-485-6340
info@briacell.com
Media Relations:
Jules Abraham
Director of Public Relations
CORE IR
917-885-7378
julesa@coreir.com
Investor Relations Contact:
CORE IR
investors@briacell.com

Primary Logo
News Provided by GlobeNewswire via QuoteMedia

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, is pleased to announce that it has received an Issue Notification from the United States Patent and Trademark Office for the composition of matter and method of use of its personalized off-the-shelf cell-based immunotherapy for cancer. The patent will issue on January 24, 2023 as US Patent No. 11,559,574 with the term extending to May 25, 2040. Additionally, BriaCell was awarded an Australian patent (Patent No. 2017224232, extends to February 27, 2037) covering composition of matter and method of use for its whole-cell cancer immunotherapy technology in Australia.

"We are extremely excited with the new patent for our novel personalized off-the-shelf cancer immunotherapy technology, which provides patent protection for the Bria-OTS™ immunotherapy cell lines under development and further validates and extends our whole-cell cancer immunotherapy technology. This is particularly important because the patent protection is not for one single type of cancer, but rather applies to multiple cancer indications," stated Dr. William V. Williams, BriaCell's President and CEO. "Unlike other personalized treatments in the marketplace and under development, our pre-made personalized cancer immunotherapies would allow more rapid treatments and may significantly extend the lives of late-stage cancer patients. We are working diligently to efficiently develop our personalized off-the-shelf immunotherapies for multiple cancers to bring hope to many late-stage cancer patients with no other treatment options."
Intellectual Property: US Patent No. 11,559,574, titled "Whole-cell cancer vaccines and methods for selection thereof," will issue on January 24, 2023, and covers the composition of matter and method of use of BriaCell's personalized off-the-shelf whole-cell immunotherapies. The novel technology involves the development of several HLA specific whole-cell immunotherapies in advance, and selection of the appropriate off-the-shelf (i.e. pre-made) immunotherapies for each patient (i.e. personalized therapy) based on the patient's HLA type using a fast and easy saliva test. Once issued, the patent will provide intellectual property protection through May 25, 2040, and a patent term extension under Hatch-Waxman potentially applies (which would extend such protection for an additional five years).
Additionally, BriaCell was awarded Australian Patent No. 2017224232, titled "Whole-cell cancer vaccines and methods for selection thereof," for claims covering composition of matter and method of use for BriaCell's whole-cell immunotherapy for cancer in Australia.
BriaCell currently holds multiple issued patents and pending patent applications to cover its whole-cell immunotherapy's composition of matter and method of use worldwide. For a summary of BriaCell's issued patents, please visit https://briacell.com/patents/ .
Bria-OTS™ Program Timelines: FDA has provided guidance regarding the development of cells and final cell-bank testing for BriaCell's Bria-OTS™ clinical-grade cell lines. Once completed in accordance with FDA's requirements, BriaCell expects to initiate the Bria-OTS™ study under an Investigational New Drug Application (IND) in the first half of 2023.
Additional Clinical Sites: BriaCell is pleased to announce that it has added Carle Cancer Institute, Urbana, Illinois, and the American Oncology Network, LLC (AON), Baltimore, Maryland, as two additional clinical sites for the screening and enrollment of advanced breast cancer patients in the randomized Phase II study of BriaCell's lead candidate, Bria-IMT™, with Incyte's PD-1 inhibitor, retifanlimab.
The following clinical sites are actively enrolling patients for BriaCell's ongoing Phase II combination study:
About BriaCell Therapeutics Corp.
BriaCell is an immuno-oncology-focused biotechnology company developing targeted and effective approaches for the management of cancer. More information is available at https://briacell.com/ .
Safe Harbor
This press release contains "forward-looking statements" that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will," "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Examples of forward-looking statements in this news release include statements that the Company makes regarding the initiation of the Company's Bria-OTS™ clinical study under an Investigational New Drug Application in the first half of 2023; the ability to treat patients more rapidly with pre-made personalized immunotherapies; the potential ability to significantly improve survival outcomes in late-stage cancer patients; and the potential patent term extension under Hatch-Waxman. Forward-looking statements are based on BriaCell's current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully under the heading "Risks and Uncertainties" in the Company's most recent Management's Discussion and Analysis, under the heading "Risk Factors" in the Company's most recent Annual Information Form, and under "Risks and Uncertainties" in the Company's other filings with the Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission, all of which are available under the Company's profiles on SEDAR at www.sedar.com and on EDGAR at www.sec.gov . Forward-looking statements contained in this announcement are made as of this date, and BriaCell Therapeutics Corp. undertakes no duty to update such information except as required under applicable law.
Neither the Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contact Information
Company Contact:
William V. Williams, MD
President & CEO
1-888-485-6340
info@briacell.com
Media Relations:
Jules Abraham
Director of Public Relations
CORE IR
917-885-7378
julesa@coreir.com
Investor Relations Contact:
CORE IR
investors@briacell.com
Primary Logo
News Provided by GlobeNewswire via QuoteMedia

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) ("BriaCell" or the "Company") a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, presented positive safetytolerability and efficacy data from its lead product candidate, Bria-IMT™, summarized in three poster sessions during the 2022 San Antonio Breast Cancer Symposium ® (SABCS).
Mayo Clinic Professor and Principal Clinical Investigator, Saranya Chumsri, M.D., stated in an audio summary of the poster: "First, this is a heavily pretreated group of end-stage metastatic breast cancer ("MBC") patients. For many of these patients, other therapies don't exist or cannot be tolerated. Bria-IMT™ does not have any theoretical cross-resistance or overlapping toxicity with other MBC treatments, which is why it is so encouraging to see responses across all MBC subtypes and a very manageable adverse event experience."

"We are impressed with the positive clinical and quality of life data in this very difficult-to-treat patient population who have failed multiple prior treatments. We're delighted that many patients stayed on our study longer than their last therapy, suggesting the Bria-IMT™ combination regimen is both well tolerated and clinically effective," stated Dr. William V. Williams, BriaCell's President and CEO. "These results have positive implications, both for our ongoing, randomized phase II study and for planned meetings with the FDA on the design of our pivotal study. Advanced MBC remains one of the most difficult cancers to treat. There remains an urgent, unmet medical need to find well-tolerated and effective treatments for these gravely ill cancer patients who have only months to live and cannot tolerate the harsh side effects of other cancer treatments."
The posters are summarized below and linked here: https://briacell.com/scientific-publications/ .
Poster 1 : Combination Study Efficacy
Title: Allogeneic, Antigen-Presenting, GM-CSF-Secreting, SV-BR-1-GM Whole Cell Therapeutic Vaccine in Advanced Metastatic Breast Cancer
Poster ID: P3-07-12
Summary: 22 advanced metastatic breast cancer patients were treated with the Bria-IMT™ regimen with PD-1 inhibitors: 11 patients with pembrolizumab and 12 patients with retifanlimab, with one patient transitioning from one combination to another. Patients had previously been heavily pre-treated with a median of 6.5 prior therapies.
Efficacy Data in all 22 patients:
Quality of Life Data: Patients who experienced disease control reported "better quality of life" scores and "less pain" with the BriaCell combination regimen. "Better quality of life", and "less pain" are life changing factors for patients with advanced metastatic breast cancer who have already failed several prior therapies and face a very short survival outlook.
To summarize, our positive clinical and quality of life data to date suggest an additive or synergistic effect of Bria-IMT™ with PD-1 inhibitors in advanced metastatic breast cancer patients and supports our strategy of using the Bria-IMT™ combination regimen with PD-1 inhibitors. We look forward to sharing additional data in the coming months, as patients continue to remain in the study and are recruited into the randomized phase II part of the study.
Poster 2 : CTCs/CAMLs Biomarker Tools
Title: Decreases in Circulating Tumor Associated Cells Predict PFS and OS in a Pooled Analysis of Phase I Clinical Trials Using SV-BR-1-GM Therapy with or without Immune Check Point Inhibitors in Metastatic Breast Cancer Patients
Poster ID: P1-05-28
Found in the blood of 90% of the advanced metastatic breast cancer patients, Cancer Associated Macrophage Like cells ("CAMLs") (Adams DL, et al. JCO abstr 3056, 2022 40:suppl 16), are suggested as an additional marker, along with Circulating Tumor Cells ("CTCs"), for predicting, evaluating, and monitoring patients' responsiveness (i.e., clinical benefit, including survival benefit) to the Bria-IMT™ regimen.
Our findings support that utilizing the CTCs/CAMLs system provides BriaCell with a powerful biomarker tool to potentially select, evaluate, and monitor patients' clinical responses to the Bria-IMT™ regimen, and could improve the probability of success in clinical studies. Most importantly, PFS and overall survival (OS) data from our findings suggest long term clinical benefit in patients treated with the Bria-IMT™ regimen in a subset of patients.
Poster 3 : Enhancing Personalized Immunotherapy (Bria-OTS2.0)
Title: Turning Tumor Cells into Antigen-Presenting Cells for Cancer Immunotherapy
Poster ID: P3-06-08
BriaCell expects the next generation (enhanced version) of our off-the-shelf personalized immunotherapies (Bria-OTS2.0) to be more effective in activating patients' immune cells, leading to faster and more effective tumor destruction in patients.
Development of a novel personalized (HLA matched with patients) immunotherapy (Bria-OTS2.0) that is off-the-shelf (i.e. premade), may represent a significant milestone in the field of personalized cancer immunotherapy. We expect superior patient efficacy using Bria-OTS2.0 because (1) it is personalized to each patient by design (HLA matching), (2) it produces multiple immune boosting factors to further activate immune cells in patients, and 3) it is manufactured in advance, and therefore available to patients upon completion of a simple, rapid, and inexpensive HLA typing saliva test.
BriaCell will seek to further evaluate Bria-OTS2.0's activity in advanced metastatic breast cancer patients.
About BriaCell Therapeutics Corp.
BriaCell is an immuno-oncology-focused biotechnology company developing targeted and effective approaches for the management of cancer. More information is available at https://briacell.com/ .
Safe Harbor
This press release contains "forward-looking statements" that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will," "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Examples of forward-looking statements in this news release include statements that the Company makes regarding the expectation of additional clinical data from the ongoing study; the potential of using the CTCs/CAMLs system as a biomarker tool to improve the probability of success in clinical studies; the long term clinical benefits of the Bria-IMT™ regiment on patients; the potential opportunity for treatment in terminal patients; the effect(s) of Bria-IMT™ on patients, including the ability of Bria-IMT™ to control disease, shrink tumors, and produce potential survival benefit; the clinical efficacy of the Bria-IMT™ combination treatment; the effectiveness of BriaCell's treatment without harmful side effects; the potential success of the Bria-IMT™ program and the ability of the Company to further advance its clinical study. Forward-looking statements are based on BriaCell's current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully under the heading "Risks and Uncertainties" in the Company's most recent Management's Discussion and Analysis, under the heading "Risk Factors" in the Company's most recent Annual Information Form, and under "Risks and Uncertainties" in the Company's other filings with the Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission, all of which are available under the Company's profiles on SEDAR at www.sedar.com and on EDGAR at www.sec.gov . Forward-looking statements contained in this announcement are made as of this date, and BriaCell Therapeutics Corp. undertakes no duty to update such information except as required under applicable law.
Neither the Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contact Information
Company Contact:
William V. Williams, MD
President & CEO
1-888-485-6340
info@briacell.com
Media Relations:
Jules Abraham
Director of Public Relations
CORE IR
917-885-7378
julesa@coreir.com
Investor Relations Contact:
CORE IR
investors@briacell.com
Primary Logo
News Provided by GlobeNewswire via QuoteMedia

IPA (IMMUNOPRECISE ANTIBODIES LTD.) ( "IPA") (NASDAQ: IPA), an advanced biotherapeutic research and technology company, today announced that BioStrand BV ("BioStrand"), an AI in silico discovery subsidiary of IPA, has entered into a research collaboration and license agreement (the "Agreement") with BriaCell Therapeutics Corp. (NASDAQ: BCTX, BCTXW) (TSX: BCT) ("BriaCell"), a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221130005423/en/
The collaboration will leverage BioStrand's LENSai™ software, built upon IPA's proprietary HYFT™ Universal Fingerprint™ technologies, and will focus on in silico antibody discovery to generate relevant clinical molecules for potential development. Under the terms of the Agreement, BioStrand and BriaCell will collaborate on the design, discovery, and development of anti-cancer antibodies. Upon successful antibody discovery, BioStrand will receive an upfront payment of US$500,000, and will be eligible to receive future success-based development milestones, including those for the submission of Investigational New Drugs (INDs), clinical milestone payments, and commercial royalties on net sales of products. Further terms are not disclosed.

"We are very excited to begin this program with BriaCell and apply our technology to the development of biologics that may have a huge clinical impact," stated Dr. Ingrid Brands, General Manager and co-founder of BioStrand. "Shortening timelines, while also integrating as much information as possible upstream to improve the efficiency of the process, is extremely important in the development of highly targeted therapies. It is a step towards realizing our long-term vision of significantly advancing precision medicine."
"We believe that BioStrand's revolutionary AI-powered technology, combined with its cutting-edge protein engineering platform, will allow us to design and discover potent anti-cancer therapeutics," stated Miguel A. Lopez-Lago, PhD, Chief Scientific Officer of BriaCell. "This approach would complement BriaCell's current immunotherapy pipeline of innovative anti-cancer therapeutics."
About BriaCell Therapeutics Corp.
BriaCell is an immuno-oncology-focused biotechnology company developing targeted and effective approaches for the management of cancer. More information is available at www. BriaCell.com
ImmunoPrecise Antibodies Ltd.
ImmunoPrecise Antibodies Ltd. has several subsidiaries in North America and Europe including entities such as Talem Therapeutics LLC, Biostrand BV, ImmunoPrecise Antibodies (Canada) Ltd. and ImmunoPrecise Antibodies (Europe) B.V. (collectively, the "IPA Family"). The IPA Family is a biotherapeutic research and technology group that leverages systems biology, multi-omics modelling and complex artificial intelligence systems to support its proprietary technologies in bioplatform-based antibody discovery. Services include highly specialized, full-continuum therapeutic biologics discovery, development, and out-licensing to support its business partners in their quest to discover and develop novel biologics against the most challenging targets. For further information, visit www.ipatherapeutics.com .
Forward Looking Information
This news release contains forward-looking statements within the meaning of applicable United States securities laws and Canadian securities laws. Forward-looking statements are often identified by the use of words such as "potential", "plans", "expects" or "does not expect", "is expected", "estimates", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Forward-looking information contained in this news release include, but are not limited to, statements relating to the anticipated impact and results of IPA's collaboration with BriaCell as well as statements relating to the amount and timing of payments and commercial royalties to be received by BriaCell. In respect of the forward-looking information contained herein, IPA has provided such statements and information in reliance on certain assumptions that management believed to be reasonable at the time.
Forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements stated herein to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. Actual results could differ materially from those currently anticipated due to a number of factors and risks, including, without limitation, the results of IPA's collaboration with BriaCell may not be as benefical as expected, milestones leading to payments from BriaCell may not all be met or at all, the amount of global net sales leading to commercial royalties may be less than expected; as well as those risks discussed in the Company's Annual Information Form dated July 28, 2022 (which may be viewed on the Company's profile at www.sedar.com ) and the Company's Form 40-F, dated July 29, 2022 (which may be viewed on the Company's profile at www.sec.gov ). Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. Accordingly, readers should not place undue reliance on forward-looking information contained in this news release. The forward-looking statements contained in this news release are made as of the date of this release and, accordingly, are subject to change after such date. The Company does not assume any obligation to update or revise any forward-looking statements, whether written or oral, that may be made from time to time by us or on our behalf, except as required by applicable law. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221130005423/en/
( ImmunoPrecise Antibodies Ltd. ):
Investor: investors@ipatherapeutics.com
(BriaCell Therapeutics Corp.) :
William V. Williams, MD
President & CEO
1-888-485-6340
info@briacell.com
Media Relations:
Jules Abraham
Director of Public Relations
CORE IR
917-885-7378
julesa@coreir.com
Investor Relations:
CORE IR
investors@briacell.com
News Provided by Business Wire via QuoteMedia

Alkaline Fuel Cell Power Corp. (NEO: PWWR) (OTCQB:ALKFF) (Frankfurt: 77R, WKN: A3CTYF) ("AFCP" or the "Company") a diversified investment platform developing affordable, renewable, and reliable energy assets and cleantech, is pleased to announce the results of voting at its annual general meeting (" AGM ") of shareholders which was held on January 25, 2023 in person in Vancouver, British Columbia and by conference call (the " Meeting "). There were 19 shareholders represented in person or by proxy at the Meeting holding 2,423,369 common shares, representing 1.39% of the Company's total issued and outstanding common shares as at the record date for the Meeting. The voting results for each matter presented at the Meeting is set out below:

Number of Directors
The board of directors received a written resignation from Joel Dumaresq on January 12, 2023. Therefor Management proposed to determine the number of seats on the board of directors be set at four (4) instead of five (5) as presented in the Company's information circulated dated December 21, 2022 and the resolution be amended accordingly.
The resolution to set the number of directors of the Company at four (4) was approved by the shareholders who voted in respect of the resolution present or represented by proxy at the Meeting.
Voting results are set out below:
Election of Directors
Each of the nominees for election as director listed in the Company's management information circular dated December 21, 2022 were elected as directors of the Company for the ensuing year until their successors are elected or appointed. Voting results are set out below:
Appointment of Auditors
Dale Matheson Carr-Hilton Labonte LLP, Chartered Professional Accountants were reappointed as Auditors of the Company for the ensuing year with their remuneration to be fixed by the Board of Directors. Voting results are set out below:
Approval of Other Matters
The resolution to transact such other business that may be brought properly before the Meeting and any adjournment or postponement of the Meeting. Voting results are set out below:
Following the AGM and the resignation of Joel Dumaresq from the Company's Board of Directors, the Audit Committee will be comprised of Troy Grant (Chair) Maciej Lis and Richard Lu. In addition, the Compensation Committee will be comprised of Matthew Fish (Chair), Maciej Lis and Troy Grant.
ABOUT ALKALINE FUEL CELL POWER CORP. (NEO: PWWR)
AFCP is a diversified investment platform developing affordable, renewable, and reliable energy assets and cleantech. We bring ‘Power to the People' today, combining a stable revenue stream with a future- forward vision to commercialize our advanced hydrogen fuel cell technology to meet the massive global market need, and ultimately generate compelling returns for investors.
AFCP operates through two global entities: Fuel Cell Power NV, a wholly owned subsidiary in Belgium, and PWWR Flow Streams ("PWWR Flow"), an AFCP brand in Canada.
AFCP is well positioned to deliver ‘Power to the People' in the global energy transition while offering a diversified cleantech growth platform for investors.
Further information is available on the Company website at https://www.fuelcellpower.com/ , and the Company encourages investors and other interested stakeholders to follow it on:
LinkedIn, Twitter, Facebook, Instagram and YouTube. Common shares are listed for trading on the NEO under the symbol " PWWR ", the OTC Venture Exchange " OTCQB " under the symbol " ALKFF " and on the Frankfurt Exchange under symbol " 77R " and " WKN A3CTYF ".
For further information, please contact:
Frank Carnevale
Chief Executive Officer
+1 (647) 531- 8264
fcarnevale@fuelcellpower.com
Forward-Looking Information
This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward-looking statements or information. In certain cases, forward-looking statements can be identified by the use of words such as "plans", "expects" or "does not expect", "is expected", "estimates", "forecasts", "intends", "anticipates", "believes" or variations of such words and phrases or statements that certain actions, events or results "may", "could", "would", "might", "occur" or "achieve". Forward-looking statements in this news release may include, but are not limited to, the issuance of RSUs, the vesting of the RSUs, statements with respect to the Company's technology, intellectual property, business plan, objectives and strategy.
Forward-looking statements and information are provided for the purpose of providing information about the current expectations and plans of management of the Company relating to the future. Readers are cautioned that reliance on such statements and information may not be appropriate for other purposes, such as making investment decisions. Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this news release. Readers are cautioned that the foregoing list of factors is not exhaustive. The forward- looking statements and information contained in this news release are made as of the date hereof and no undertaking is given to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws. The forward-looking statements or information contained in this news release are expressly qualified by this cautionary statement.
NEITHER THE NEO EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE NEO EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
Primary Logo
News Provided by GlobeNewswire via QuoteMedia

Alkaline Fuel Cell Power Corp. (NEO: PWWR) (OTCQB:ALKFF) (Frankfurt: 77R, WKN: A3CTYF) ("AFCP" or the "Company") a diversified investment platform developing affordable, renewable, and reliable energy assets and cleantech, announces the resignation of Joel Dumaresq as director, effective January 12, 2023. Mr. Dumaresq will remain as the Chief Financial Officer of the Company while the Company seeks a suitable replacement.
ABOUT Alkaline Fuel Cell Power CORP.
The Company is a diversified investment platform developing affordable, renewable, and reliable energy assets and cleantech. We bring ‘Power to the People' today, combining a stable revenue stream with a future- forward vision to commercialize our advanced hydrogen fuel cell technology to meet the massive global market need, and ultimately generate compelling returns for investors.

The Company operates through two global entities: Fuel Cell Power NV, a wholly owned subsidiary in Belgium, and PWWR Flow Streams ("PWWR Flow"), a Company brand in Canada.
The Company is well positioned to deliver ‘Power to the People' in the global energy transition while offering a diversified cleantech growth platform for investors.
Further information is available on the Company website at https://www.fuelcellpower.com/ , and the Company encourages investors and other interested stakeholders to follow it on:
LinkedIn, Twitter, Facebook, Instagram and YouTube. Common shares are listed for trading on the NEO under the symbol " PWWR ", the OTC Venture Exchange " OTCQB " under the symbol " ALKFF " and on the Frankfurt Exchange under symbol " 77R " and " WKN A3CTYF ".
For further information, please contact:

Frank Carnevale
Chief Executive Officer
+1 (647) 531-8264
fcarnevale@fuelcellpower.com
Forward-Looking Information
This news release contains forward‐looking statements and forward‐looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward‐looking statements or information. In certain cases, forward-looking statements can be identified by the use of words such as "plans", "expects" or "does not expect", "is expected", "estimates", "forecasts", "intends", "anticipates", "believes" or variations of such words and phrases or statements that certain actions, events or results "may", "could", "would", "might", "occur" or "achieve". Forward-looking statements may include, but are not limited to, statements with respect to the Company's technology, intellectual property, business plan, objectives and strategy.
Forward-looking statements and information are provided for the purpose of providing information about the current expectations and plans of management of the Company relating to the future. Readers are cautioned that reliance on such statements and information may not be appropriate for other purposes, such as making investment decisions. Since forward‐looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. Accordingly, readers should not place undue reliance on the forward‐looking statements and information contained in this news release. Readers are cautioned that the foregoing list of factors is not exhaustive. The forward‐looking statements and information contained in this news release are made as of the date hereof and no undertaking is given to update publicly or revise any forward‐looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws. The forward-looking statements or information contained in this news release are expressly qualified by this cautionary statement.
NEITHER THE NEO EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE NEO EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Primary Logo
News Provided by GlobeNewswire via QuoteMedia

Alkaline Fuel Cell Power Corp. (NEO: PWWR) (OTCQB:ALKFF) (Frankfurt: 77R, WKN: A3CTYF) (" AFCP " or the " Company "), a diversified investment platform developing affordable, renewable, and reliable energy assets and cleantech, is pleased to announce that the Company has granted an aggregate of 9,541,557 restricted share units (" RSUs ") to certain arm's-length consultants of the Company (each, a " Consultant ").
The RSUs will vest in accordance with the terms of each Consultant's RSU agreement and in accordance with the Company's 2021 RSU Plan. Upon vesting, each RSU entitles the holder thereof to receive one common share in the capital of the Company.

ABOUT ALKALINE FUEL CELL POWER CORP. (NEO: PWWR)
AFCP is a diversified investment platform developing affordable, renewable, and reliable energy assets and cleantech. We bring ‘Power to the People' today, combining a stable revenue stream with a future- forward vision to commercialize our advanced hydrogen fuel cell technology to meet the massive global market need, and ultimately generate compelling returns for investors.
AFCP operates through two global entities: Fuel Cell Power NV, a wholly owned subsidiary in Belgium, and PWWR Flow Streams ("PWWR Flow"), an AFCP brand in Canada.
AFCP is well positioned to deliver ‘Power to the People' in the global energy transition while offering a diversified cleantech growth platform for investors.
Further information is available on the Company website at https://www.fuelcellpower.com/ , and the Company encourages investors and other interested stakeholders to follow it on:
LinkedIn, Twitter, Facebook, Instagram and YouTube. Common shares are listed for trading on the NEO under the symbol " PWWR ", the OTC Venture Exchange " OTCQB " under the symbol " ALKFF " and on the Frankfurt Exchange under symbol " 77R " and " WKN A3CTYF ".
For further information, please contact:
Frank Carnevale
Chief Executive Officer
+1 (647) 531- 8264
fcarnevale@fuelcellpower.com
Forward-Looking Information
This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward-looking statements or information. In certain cases, forward-looking statements can be identified by the use of words such as "plans", "expects" or "does not expect", "is expected", "estimates", "forecasts", "intends", "anticipates", "believes" or variations of such words and phrases or statements that certain actions, events or results "may", "could", "would", "might", "occur" or "achieve". Forward-looking statements in this news release may include, but are not limited to, the issuance of RSUs, the vesting of the RSUs, statements with respect to the Company's technology, intellectual property, business plan, objectives and strategy.
Forward-looking statements and information are provided for the purpose of providing information about the current expectations and plans of management of the Company relating to the future. Readers are cautioned that reliance on such statements and information may not be appropriate for other purposes, such as making investment decisions. Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this news release. Readers are cautioned that the foregoing list of factors is not exhaustive. The forward- looking statements and information contained in this news release are made as of the date hereof and no undertaking is given to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws. The forward-looking statements or information contained in this news release are expressly qualified by this cautionary statement.
NEITHER THE NEO EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE NEO EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
Primary Logo
News Provided by GlobeNewswire via QuoteMedia

Alkaline Fuel Cell Power Corp. (NEO: PWWR) (OTCQB:ALKFF) (Frankfurt: 77R, WKN: A3CTYF) (" PWWR " or the " Company "), a diversified investment platform developing affordable, renewable, and reliable energy assets and cleantech, is pleased to announce that its wholly owned Belgium subsidiary, Fuel Cell Power NV (" FCP NV "), has launched the prototype of its micro-combined heat and power (" CHP ") fuel cell, named Jupiter 1.0 .
"Alkaline Fuel Cell Power is proud to present the prototype of our fuel cell system for homes and small buildings – Jupiter 1.0," stated Frank Carnevale, Chief Executive Officer of PWWR. "The Jupiter 1.0 prototype will be piloted with select strategic partners to demonstrate the advantages of delivering green hydrogen to homes and small buildings, globally. We thank staff for their dedication and effort to complete this important milestone on time."

FCP NV development team with completed fuel cell system prototype - Jupiter 1.0

Figure 1- FCP NV development team with completed fuel cell system prototype – Jupiter 1.0
Jupiter 1.0
The planet Jupiter is made up of roughly 90% hydrogen, and similarly, this PWWR fuel cell converts hydrogen to heat and electricity at approximately 90% efficiency. Jupiter 1.0 is built to supply power during peak demand periods and serves as a back-up when required for homes and small buildings.
Jupiter 1.0 has successfully demonstrated its capabilities by powering several appliances and providing hot water within the Company's Belgian facility. At capacity, Jupiter 1.0 is expected to deliver approximately 7kW for the first hour of use, with a 4kW electrical output afterward representing approximately 3.2 kWh equivalent in heating output. The use of internal batteries enables Jupiter 1.0 to deliver higher peak power when called upon in the first hour of use. Over the coming months, additional enhancements will be made to the system prior to submission for CE-certification (a regulatory standard that verifies certain products are safe for sale and use in the European Economic Area) and prior to pilot projects.
PWWR has been working to optimize innovation for hydrogen-powered fuel cells that operate in an alkaline environment, which offer meaningful cost benefits. Such technology, and therefore Jupiter 1.0, requires fewer components compared to conventional fuel cells and also eliminates the need for expensive, precious metals such as platinum which have traditionally been required in the electrodes. PWWR's systems will therefore be more cost-effective to build and offer a competitive advantage over existing fuel cells. Jupiter 1.0 is currently stationed in the FCP NV plant in Belgium.
Jupiter 1.0 delivering power and heat to appliances and a boiler

Figure 2- Jupiter 1.0 delivering power and heat to appliances and a boiler
Pilot Projects
As announced on September 20, 2022 and November 22, 2022 , PWWR is in the process of negotiating two pilot projects which will demonstrate the mutual technologies and business cases with the use of hydrogen extraction from natural gas pipelines, and the use of ammonia converted to hydrogen as a back-up power solution for remote sites. PWWR, in coordination with its partners, continues to narrow down sites for these pilots, and will provide ongoing updates as developments are confirmed.
Management Update
With the launch of Jupiter 1.0, PWWR moves into a more strategic focus on the completion of prototypes for CE-certification and deployment in pilot projects. Jo Verstappen, Managing Director of FCP NV has resigned in his role. The Company offers its gratitude and appreciation for his guidance to launch the prototype. Frank Carnevale, Chief Executive Officer of Alkaline Fuel Cell Power Corp, has assumed management of FCP NV, and is actively reviewing and developing the commercialization strategies and tactics to bring Jupiter 1.0 and fuel cell generator to markets, globally.
ABOUT ALKALINE FUEL CELL POWER CORP.
The Company is a diversified investment platform developing affordable, renewable, and reliable energy assets and cleantech. We bring ‘Power to the People' today, combining a stable revenue stream with a future-forward vision to commercialize our advanced hydrogen fuel cell technology to meet the massive global market need, and ultimately generate compelling returns for investors.
The Company operates through two global entities: Fuel Cell Power NV, a wholly owned subsidiary in Belgium, and PWWR Flow Streams ("PWWR Flow"), a Company brand in Canada.
The Company is well positioned to deliver ‘Power to the People' in the global energy transition while offering a diversified cleantech growth platform for investors.
Further information is available on the Company website at https://www.fuelcellpower.com/ , and the Company encourages investors and other interested stakeholders to follow it on:
LinkedIn, Twitter, Facebook, Instagram and YouTube. Common shares are listed for trading on the NEO under the symbol " PWWR ", the OTC Venture Exchange " OTCQB " under the symbol " ALKFF " and on the Frankfurt Exchange under symbol " 77R " and " WKN A3CTYF ".
For further information, please contact:
Frank Carnevale
Chief Executive Officer
Alkaline Fuel Cell Power Corp
+1 (647) 531- 8264
fcarnevale@fuelcellpower.com
www.fuelcellpower.com
Forward-Looking Information
This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward-looking statements or information. In certain cases, forward-looking statements can be identified by the use of words such as "plans", "expects" or "does not expect", "is expected", "estimates", "forecasts", "intends", "anticipates", "believes" or variations of such words and phrases or statements that certain actions, events or results "may", "could", "would", "might", "occur" or "achieve". Forward-looking statements in this news release may include, but are not limited to, expectations and intended use of CHP system, Juniper 1.0; efficiencies of the CHP system; the ability to successfully bring the CHP system to market; future pilot projects of the Company and future strategic initiatives and plans of the Company and FCP NV.
Forward-looking statements and information are provided for the purpose of providing information about the current expectations and plans of management of the Company relating to the future. Readers are cautioned that reliance on such statements and information may not be appropriate for other purposes, such as making investment decisions. Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this news release. Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements and information contained in this news release are made as of the date hereof and no undertaking is given to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws. The forward-looking statements or information contained in this news release are expressly qualified by this cautionary statement.
NEITHER THE NEO EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE NEO EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
Photos accompanying this announcement are available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/418691fc-3249-4b23-89fd-4d33359eae01
https://www.globenewswire.com/NewsRoom/AttachmentNg/dd7508c7-5de0-4efd-b162-95ac0fb6b44a
Primary Logo
News Provided by GlobeNewswire via QuoteMedia

Highlights
nano one® Materials Corp. ("nano one" or the "Company"), a clean technology company focused on the production of cathode materials used in lithium-ion batteries, is pleased to provide an update on the reorganization of the combined teams, and the transformation of the Candiac lithium iron phosphate ("LFP") facility to the One-Pot process, following completion of the acquisition previously announced on November 1, 2022
Mr. Denis Geoffroy, Chief Commercialization Officer said, "The team at Candiac has tremendous experience in LFP, having developed two different processes, built the first and only LFP plant in North America and operated it for 10 years. Adding the cost and environmental benefits of the One-Pot process, they are excited to be pioneering a new generation of LFP to have a meaningful impact in the energy transition. We have re-organized nano one to align everyone with our strategic objectives, are happy with the progress on integration, and are executing successfully on our LFP commercialization plans with the aim of providing long-term value to our supportive shareholders."

Leveraging the deep experience of the Quebec operational team, action plans are being implemented to convert the Candiac facility to nano one's patented One-Pot process to accelerate the commercialization of nano one's LFP technology. Candiac assets and know-how will help design turn-key systems to address, and align with, projected global LFP cathode market demand. This will support America's efforts to ‘friendshore' battery supply chain production through the Inflation Reduction Act ("IRA") and other international initiatives.
LFP trials with the One-Pot technology will start in January 2023. Initial plant preparations are complete, including process hazard studies, for the use of the existing commercial scale reactors for larger scale trials beginning in Q1 2023. Results from this work will provide nano one with valuable insights for the next stage of trials, pilot production and advanced engineering. Large One-Pot reactors have been designed and ordered, with installation, integration and commissioning expected in Q3 2023 for industrial pilot scale LFP production. This builds on existing development work and supports evaluation and validation work with potential customers. Certain equipment in the Candiac facility will not be needed for the One-Pot process and is currently being decommissioned and removed, while procurement of new equipment is ongoing. nano one has initiated a third-party evaluation of the assets that will be used for the industrial pilot and is planning to sell unneeded equipment in the One-Pot process.
All raw materials ordered for the first trials have now been received on site and small quantities will be utilized for training purposes before advancing to larger volumes.
The Candiac plant is currently the only existing LFP production facility in North America. It consists of an 80,000 square foot production plant and the most experienced LFP operational team in the world, outside of China. The plant and team are located 20 km outside of Montréal, in Candiac, Québec, and are strategically aligned with Canada's "Mines to Mobility" initiative.
Business Development Bank of Canada (BDC), as previously announced, is working with nano one on the continued integration of the Candiac and Burnaby teams, and objectives for the first 3 months are substantially complete, on-time and on-budget. The work has been well informed, collaborative and aligned with business plans, and it has led to a smooth transition as Candiac transforms to the One-Pot process and as Burnaby takes on valuable scale-up and production know-how. The integration team is proud to announce that all staff have been retained and that employee know-how in both facilities is complimentary, accretive and mutually aligned with nano one's strategic objectives and will provide long-term stakeholder value.
"I am pleased to report that these first few months of integration have gone as well as we had anticipated, thanks to careful planning, collaboration, experience and focus," said Chief Operating Officer, Alex Holmes. "The newly combined team benefits from common goals, a culture of learning and are building on the richness of each other's experiences."
With at least eight[1] auto OEM's publicly stating they are using, or are about to use, LFP, the world is already witnessing the rise of LFP cathode in cells as a major segment of the lithium-ion battery market. Canada's "Mines to Mobility" plan and America's IRA are two examples of government support and policy imperatives to shift the manufacturing of electric vehicles, energy storage, their battery components, materials and critical minerals to domestic markets and like-minded nation partners. nano one's Candiac team and facility are key building blocks in this transformation and are being positioned to change how the world makes battery materials.
Mr. Holmes continued "We are leveraging our know-how and advanced technology to address the inherent scale-up challenges of a Terawatt hour world. Until now, LFP batteries have been known for their low cost, safety and longevity, but with nano one's innovations, we believe we can lead the transformation of the domestic LFP supply chain by further driving down cost, supply chain risk, energy intensity and environmental footprint for the cleanest, greenest and most secure supply chain on the planet."
About nano one®
Nano One Materials Corp (nano one) is a clean technology company with a patented, scalable and low carbon intensity industrial process for the low-cost production of high-performance lithium-ion battery cathode materials. It employs approximately 120 people at its innovation and commercialization hubs in British Columbia and Québec, including the only LFP plant and production team in North America. It has strategic collaborations and partnerships, that include Rio Tinto, BASF, Umicore, CBMM and various automotive OEMs.
nano one's technology is applicable to electric vehicles, energy storage, consumer electronics and next generation batteries in the global push for a zero-emission future. Its One-Pot process, its coated single crystal materials, and its Metal to Cathode Active Material (M2CAM®) technologies address fundamental performance needs and supply chain constraints; they also reduce equipment and raw material costs, operating expenses, and carbon intensity; and they eliminate a significant waste stream for a much-improved environmental footprint.
The Company aims to pilot and demonstrate its technology as turn-key CAM production solutions for license, joint venture and independent production opportunities. This leverages Canadian talent, critical minerals, renewable energy, and a thriving ecosystem with access to large emerging markets in North America, Europe and the Indo-Pacific region. nano one has received funding from the Government of Canada and Government of British Columbia.
For more information, please visit www.nanoone.ca
Company Contact:
Paul Guedes
info@nanoone.ca
(604) 420-2041
Certain information contained herein may constitute "forward-looking information" and "forward-looking statements" within the meaning of applicable securities legislation. All statements, other than statements of historical fact, are forward-looking statements. Forward-looking information in this news release includes, but is not limited to, statements with respect to: continuing success of the integration of the Candiac; timelines and expectations for the transition of the Candiac facility including trials for the One-Pot process; the development of technology, supply chains, and plans for construction, scale-up and operation of cathode production facilities; successful current and future collaborations that may happen with OEM's, miners or others; the execution of the Company's plans which are contingent on support and grants, and the commercialization of the Company's technology and patents. Generally, forward-looking information can be identified by the use of terminology such as 'believe', 'expect', 'anticipate', 'plan', 'intend', 'continue', 'estimate', 'may', 'will', 'should', 'ongoing', ‘target', ‘goal', ‘encouraged', ‘projected', ‘potential' or variations of such words and phrases or statements that certain actions, events or results "will" occur. Forward-looking statements are based on the current opinions and estimates of management as of the date such statements are made are not, and cannot be, a guarantee of future results or events. Forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information, including but not limited to: general and global economic and regulatory changes; next steps and timely execution of the Company's business plans; the development of technology, supply chains, and plans for construction and operation of cathode production facilities; successful current or future collaborations that may happen with OEM's, miners or others; the execution of the Company's plans which are contingent on support and grants; the Company's ability to achieve its stated goals; the commercialization of the Company's technology and patentsvialicense, joint venture and independent production; anticipated global demand and projected growth for LFP batteries and other risk factors as identified in nano one's MD&A and its Annual Information Form dated March 28, 2022, both for the year ended December 31, 2021, and in recent securities filings for the Companies which are available at www.sedar.com. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. The Company does not undertake any obligation to update any forward-looking statements or forward-looking information that is incorporated by reference herein, except as required by applicable securities laws. Investors should not place undue reliance on forward-looking statements.
[1] Based on data compiled by the Company.
SOURCE:nano one materials corp.
News Provided by ACCESSWIRE via QuoteMedia

Alkaline Fuel Cell Power Corp. (NEO: PWWR) (OTCQB:ALKFF) (Frankfurt: 77R, WKN: A3CTYF) (" PWWR " or the " Company "), a diversified investment platform developing affordable, renewable, and reliable energy assets and cleantech, is pleased to announce that its wholly owned Belgium subsidiary, Fuel Cell Power NV (" FCP NV "), has launched the prototype of its micro-combined heat and power (" CHP ") fuel cell, named Jupiter 1.0 .
"Alkaline Fuel Cell Power is proud to present the prototype of our fuel cell system for homes and small buildings – Jupiter 1.0," stated Frank Carnevale, Chief Executive Officer of PWWR. "The Jupiter 1.0 prototype will be piloted with select strategic partners to demonstrate the advantages of delivering green hydrogen to homes and small buildings, globally. We thank staff for their dedication and effort to complete this important milestone on time."

FCP NV development team with completed fuel cell system prototype - Jupiter 1.0

Figure 1- FCP NV development team with completed fuel cell system prototype – Jupiter 1.0
Jupiter 1.0
The planet Jupiter is made up of roughly 90% hydrogen, and similarly, this PWWR fuel cell converts hydrogen to heat and electricity at approximately 90% efficiency. Jupiter 1.0 is built to supply power during peak demand periods and serves as a back-up when required for homes and small buildings.
Jupiter 1.0 has successfully demonstrated its capabilities by powering several appliances and providing hot water within the Company's Belgian facility. At capacity, Jupiter 1.0 is expected to deliver approximately 7kW for the first hour of use, with a 4kW electrical output afterward representing approximately 3.2 kWh equivalent in heating output. The use of internal batteries enables Jupiter 1.0 to deliver higher peak power when called upon in the first hour of use. Over the coming months, additional enhancements will be made to the system prior to submission for CE-certification (a regulatory standard that verifies certain products are safe for sale and use in the European Economic Area) and prior to pilot projects.
PWWR has been working to optimize innovation for hydrogen-powered fuel cells that operate in an alkaline environment, which offer meaningful cost benefits. Such technology, and therefore Jupiter 1.0, requires fewer components compared to conventional fuel cells and also eliminates the need for expensive, precious metals such as platinum which have traditionally been required in the electrodes. PWWR's systems will therefore be more cost-effective to build and offer a competitive advantage over existing fuel cells. Jupiter 1.0 is currently stationed in the FCP NV plant in Belgium.
Jupiter 1.0 delivering power and heat to appliances and a boiler

Figure 2- Jupiter 1.0 delivering power and heat to appliances and a boiler
Pilot Projects
As announced on September 20, 2022 and November 22, 2022 , PWWR is in the process of negotiating two pilot projects which will demonstrate the mutual technologies and business cases with the use of hydrogen extraction from natural gas pipelines, and the use of ammonia converted to hydrogen as a back-up power solution for remote sites. PWWR, in coordination with its partners, continues to narrow down sites for these pilots, and will provide ongoing updates as developments are confirmed.
Management Update
With the launch of Jupiter 1.0, PWWR moves into a more strategic focus on the completion of prototypes for CE-certification and deployment in pilot projects. Jo Verstappen, Managing Director of FCP NV has resigned in his role. The Company offers its gratitude and appreciation for his guidance to launch the prototype. Frank Carnevale, Chief Executive Officer of Alkaline Fuel Cell Power Corp, has assumed management of FCP NV, and is actively reviewing and developing the commercialization strategies and tactics to bring Jupiter 1.0 and fuel cell generator to markets, globally.
ABOUT ALKALINE FUEL CELL POWER CORP.
The Company is a diversified investment platform developing affordable, renewable, and reliable energy assets and cleantech. We bring ‘Power to the People' today, combining a stable revenue stream with a future-forward vision to commercialize our advanced hydrogen fuel cell technology to meet the massive global market need, and ultimately generate compelling returns for investors.
The Company operates through two global entities: Fuel Cell Power NV, a wholly owned subsidiary in Belgium, and PWWR Flow Streams ("PWWR Flow"), a Company brand in Canada.
The Company is well positioned to deliver ‘Power to the People' in the global energy transition while offering a diversified cleantech growth platform for investors.
Further information is available on the Company website at https://www.fuelcellpower.com/ , and the Company encourages investors and other interested stakeholders to follow it on:
LinkedIn, Twitter, Facebook, Instagram and YouTube. Common shares are listed for trading on the NEO under the symbol " PWWR ", the OTC Venture Exchange " OTCQB " under the symbol " ALKFF " and on the Frankfurt Exchange under symbol " 77R " and " WKN A3CTYF ".
For further information, please contact:
Frank Carnevale
Chief Executive Officer
Alkaline Fuel Cell Power Corp
+1 (647) 531- 8264
fcarnevale@fuelcellpower.com
www.fuelcellpower.com
Forward-Looking Information
This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward-looking statements or information. In certain cases, forward-looking statements can be identified by the use of words such as "plans", "expects" or "does not expect", "is expected", "estimates", "forecasts", "intends", "anticipates", "believes" or variations of such words and phrases or statements that certain actions, events or results "may", "could", "would", "might", "occur" or "achieve". Forward-looking statements in this news release may include, but are not limited to, expectations and intended use of CHP system, Juniper 1.0; efficiencies of the CHP system; the ability to successfully bring the CHP system to market; future pilot projects of the Company and future strategic initiatives and plans of the Company and FCP NV.
Forward-looking statements and information are provided for the purpose of providing information about the current expectations and plans of management of the Company relating to the future. Readers are cautioned that reliance on such statements and information may not be appropriate for other purposes, such as making investment decisions. Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this news release. Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements and information contained in this news release are made as of the date hereof and no undertaking is given to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws. The forward-looking statements or information contained in this news release are expressly qualified by this cautionary statement.
NEITHER THE NEO EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE NEO EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
Photos accompanying this announcement are available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/418691fc-3249-4b23-89fd-4d33359eae01
https://www.globenewswire.com/NewsRoom/AttachmentNg/dd7508c7-5de0-4efd-b162-95ac0fb6b44a
Primary Logo
News Provided by GlobeNewswire via QuoteMedia

Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies. 

source

Leave a Reply

Your email address will not be published. Required fields are marked *